RxDoctor Payments Data

Robert Yohai, MD

Ophthalmology · Santa Rosa, CANPI 1023030301

Payments from drug & device makers

$631in general payments, 2019–2025

Across 7 payments — averaging $90.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Carl Zeiss Meditec, Inc.$357
  • Alcon$182
  • Johnson & Johnson Surgical Vision, Inc.$69
  • Amgen$24

What the payments were for

  • Travel & lodging$122%
  • Food & beverage$61998%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$631 in reported general payments places this provider in the 35th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$426,943
Medicare patients
751
Services billed
4,144

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost45$23,414
RestasisCyclosporine23$21,116
SimbrinzaBrinzolamide/Brimonidine Tart38$15,265
RocklatanNetarsudil Mesylat/Latanoprost24$10,024
Prednisolone Acetate204$9,741
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol57$8,675
Timolol Maleate392$8,480
RhopressaNetarsudil Mesylate13$7,284
Latanoprost382$5,373
CombiganBrimonidine Tartrate/Timolol21$5,103
Tobramycin-DexamethasoneTobramycin/Dexamethasone87$4,010
Fluorometholone37$3,507
Cyclosporine15$3,058
Loteprednol Etabonate13$2,249
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat113$1,815

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AlconSimbrinza$182$15,26538 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Santa Rosa

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →